139 related articles for article (PubMed ID: 11020468)
1. Relationship between soluble thrombomodulin in plasma and coagulation or fibrinolysis in type 2 diabetes.
Aso Y; Fujiwara Y; Tayama K; Takebayashi K; Inukai T; Takemura Y
Clin Chim Acta; 2000 Nov; 301(1-2):135-45. PubMed ID: 11020468
[TBL] [Abstract][Full Text] [Related]
2. Impaired fibrinolytic compensation for hypercoagulability in obese patients with type 2 diabetes: association with increased plasminogen activator inhibitor-1.
Aso Y; Matsumoto S; Fujiwara Y; Tayama K; Inukai T; Takemura Y
Metabolism; 2002 Apr; 51(4):471-6. PubMed ID: 11912556
[TBL] [Abstract][Full Text] [Related]
3. A possible role of thrombin-activatable fibrinolysis inhibitor in disturbances of fibrinolytic system in renal transplant recipients.
Hryszko T; Malyszko J; Malyszko JS; Brzosko S; Pawlak K; Mysliwiec M
Nephrol Dial Transplant; 2001 Aug; 16(8):1692-6. PubMed ID: 11477176
[TBL] [Abstract][Full Text] [Related]
4. Circulating thrombomodulin and hematological alterations in type 2 diabetic patients with retinopathy.
Fujiwara Y; Tagami S; Kawakami Y
J Atheroscler Thromb; 1998; 5(1):21-8. PubMed ID: 10077454
[TBL] [Abstract][Full Text] [Related]
5. Coagulation and inflammation in overt diabetic nephropathy: association with hyperhomocysteinemia.
Aso Y; Yoshida N; Okumura K; Wakabayashi S; Matsutomo R; Takebayashi K; Inukai T
Clin Chim Acta; 2004 Oct; 348(1-2):139-45. PubMed ID: 15369747
[TBL] [Abstract][Full Text] [Related]
6. High plasma homocysteine concentrations are associated with plasma concentrations of thrombomodulin in patients with type 2 diabetes and link diabetic nephropathy to macroangiopathy.
Okumura K; Aso Y
Metabolism; 2003 Nov; 52(11):1517-22. PubMed ID: 14624417
[TBL] [Abstract][Full Text] [Related]
7. Thrombomodulin: a linker of coagulation and fibrinolysis and predictor of risk of arterial thrombosis.
Wu KK; Matijevic-Aleksic N
Ann Med; 2000 Dec; 32 Suppl 1():73-7. PubMed ID: 11209986
[TBL] [Abstract][Full Text] [Related]
8. Influence of ramipril on the course of plasma thrombomodulin in patients with diabetes mellitus.
Borcea V; Morcos M; Isermann B; Henkels M; Ziegler S; Zumbach M; Amiral J; Längst KD; Seiz W; Ziegler R; Wahl P; Nawroth PP
Vasa; 1999 Aug; 28(3):172-80. PubMed ID: 10483322
[TBL] [Abstract][Full Text] [Related]
9. Increased plasma thrombin-activatable fibrinolysis inhibitor levels in normotensive type 2 diabetic patients with microalbuminuria.
Yano Y; Kitagawa N; Gabazza EC; Morioka K; Urakawa H; Tanaka T; Katsuki A; Araki-Sasaki R; Hori Y; Nakatani K; Taguchi O; Sumida Y; Adachi Y
J Clin Endocrinol Metab; 2003 Feb; 88(2):736-41. PubMed ID: 12574207
[TBL] [Abstract][Full Text] [Related]
10. Thrombomodulin in human plasma contributes to inhibit fibrinolysis through acceleration of thrombin-dependent activation of plasma procarboxypeptidase B.
Hosaka Y; Takahashi Y; Ishii H
Thromb Haemost; 1998 Feb; 79(2):371-7. PubMed ID: 9493593
[TBL] [Abstract][Full Text] [Related]
11. Plasma thrombomodulin: a marker for microvascular complications in diabetes mellitus.
Gabat S; Keller C; Kempe HP; Amiral J; Ziegler R; Ritz E; Bergis KH; Wahl P; Nawroth P
Vasa; 1996; 25(3):233-41. PubMed ID: 8795304
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological Differentiation of Thrombomodulin Alfa and Activated Protein C on Coagulation and Fibrinolysis In Vitro.
Tanaka K; Tawara S; Tsuruta K; Hoppensteadt D; Fareed J
Clin Appl Thromb Hemost; 2018 Sep; 24(6):859-866. PubMed ID: 29683037
[TBL] [Abstract][Full Text] [Related]
13. [Studies on coagulation-fibrinolytic system in diabetic nephropathy--with reference to plasma TAT and alpha 2PIC].
Watanabe S; Ogihara T; Iyori S; Kaneshige H; Nomoto Y; Sakai H
Nihon Jinzo Gakkai Shi; 1990 Sep; 32(9):995-9. PubMed ID: 2148199
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of elevation of serum and urinary concentrations of soluble thrombomodulin in diabetic patients: possible application as a marker for vascular endothelial injury.
Aso Y; Inukai T; Takemura Y
Metabolism; 1998 Mar; 47(3):362-5. PubMed ID: 9500578
[TBL] [Abstract][Full Text] [Related]
15. Relationship between plasma soluble thrombomodulin levels and insulin resistance syndrome in type 2 diabetes: a comparison with von Willebrand factor.
Aso Y; Fujiwara Y; Tayama K; Takanashi K; Inukai T; Takemura Y
Exp Clin Endocrinol Diabetes; 2001; 109(4):210-6. PubMed ID: 11453033
[TBL] [Abstract][Full Text] [Related]
16. Coagulation and fibrinolysis parameters in type 2 diabetic patients with and without diabetic vascular complications.
Erem C; Hacihasanoğlu A; Celik S; Ovali E; Ersöz HO; Ukinç K; Deger O; Telatar M
Med Princ Pract; 2005; 14(1):22-30. PubMed ID: 15608477
[TBL] [Abstract][Full Text] [Related]
17. Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin.
Mosnier LO; Meijers JC; Bouma BN
Thromb Haemost; 2001 Jan; 85(1):5-11. PubMed ID: 11204587
[TBL] [Abstract][Full Text] [Related]
18. Protein C activation in NIDDM patients.
Gabazza EC; Takeya H; Deguchi H; Sumida Y; Taguchi O; Murata K; Nakatani K; Yano Y; Mohri M; Sata M; Shima T; Nishioka J; Suzuki K
Diabetologia; 1996 Dec; 39(12):1455-61. PubMed ID: 8960826
[TBL] [Abstract][Full Text] [Related]
19. Insulin resistance and changes in the blood coagulation-fibrinolysis system after a glucose clamp technique in patients with type 2 diabetes mellitus.
Takanashi K; Inukai T
J Med; 2000; 31(1-2):45-62. PubMed ID: 10998755
[TBL] [Abstract][Full Text] [Related]
20. [Study on coagulation fibrinolytic systems in predialysis patients with chronic renal failure--comparison between patients with chronic glomerulonephritis and patients with diabetic nephropathy].
Nagake Y; Makino H; Yorioka N; Nomura S; Osawa G; Yamakido M; Kawasaki H; Kato Y; Matsuzaki M; Shikata K; Uemasu J; Somiya H; Fujii Z; Hayashida S; Nasu T; Oyabu Y; Nitta Y; Kawanishi H; Usui K; Fujiwara K; Takasugi N; Kanehara K; Hamaguchi N; Kumagai I; Ota Z
Nihon Jinzo Gakkai Shi; 1997 Jul; 39(5):474-82. PubMed ID: 9283213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
